{"id":"NCT03565900","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","officialTitle":"A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-12","primaryCompletion":"2021-11-04","completion":"2021-11-04","firstPosted":"2018-06-21","resultsPosted":"2022-10-20","lastUpdate":"2023-07-28"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":[]},{"type":"BIOLOGICAL","name":"PNEUMOVAX™23","otherNames":[]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of PNEUMOVAX™23 (administered as open label, 12 months after allogeneic hematopoietic stem cell transplant \\[allo-HSCT\\] in participants who do not develop chronic graft-versus-host disease \\[GVHD\\]).","primaryOutcome":{"measure":"Adult Participants: Percentage of Participants With a Solicited Injection-site Adverse Event Following Any of the First 3 Doses With V114 or Prevnar 13™","timeFrame":"Up to 5 days after any of the Day 1, Day 30, or Day 60 vaccinations (V114 or Prevnar 13™)","effectByArm":[{"arm":"V114 (Adult)","deltaMin":20.6,"sd":null},{"arm":"Prevnar 13™ (Adult)","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":52,"countries":["United States","Australia","Belgium","Brazil","Canada","Colombia","France","Germany","Mexico","Sweden"]},"refs":{"pmids":["37338158"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":131},"commonTop":["Injection site pain","Myalgia","Fatigue","Headache","Injection site swelling"]}}